Isomorphic Labs Appoints Colin Murdoch as First President to Accelerate AI-Driven Drug Discovery

On March 11, Isomorphic Labs, an AI pharmaceutical company under Alphabet, announced the appointment of Colin Murdoch as the new president of the company.

It is worth noting that,This is also the first president appointed by Isomorphic.。

At the same time, Colin will continue to serve as the Chief Business Officer of Google DeepMind.

Isomorphic stated that Colin had previously led the team in delivering the translation and application of AlphaFold, playing an indispensable role in laying the groundwork for Isomorphic Labs' progress.

As President, Colin will be responsible for day-to-day business operations, working to execute Isomorphic’s strategy and vision under the guidance of CEO Demis Hassabis.

Colin's leadership plan is to continue with the company's original idea: to bring together the smartest talents from around the world, the best expertise in machine learning and artificial intelligence, as well as tremendous scientific expertise in chemistry and biology, to build this powerful unit and start transforming the way drug discovery is conducted.

Colin said, "We are fully committed to investing in scientific research and technology development, as well as the effective transformation and application of this technology, to provide treatments for the pharmaceutical industry and the world, with the potential to improve the lives of millions of people. It is truly an honor to be part of this team, and I am very excited to get started."

Colin also mentioned that Alphabet stillHowever, he is a strong supporter of Isomorphic Labs' financial resources."Isomorphic Labs stems from DeepMind's groundbreaking work on AlphaFold."There has always been a very special relationship between our two companies, and we will continue to collaborate where it makes sense.”